Protalix BioTherapeutics, Inc. (PLX)
PLX Stock Price Chart
Explore Protalix BioTherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze PLX price movements and trends.
PLX Company Profile
Discover essential business fundamentals and corporate details for Protalix BioTherapeutics, Inc. (PLX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 May 1998
Employees
213.00
Website
https://www.protalix.comCEO
Dror Bashan
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
PLX Financial Timeline
Browse a chronological timeline of Protalix BioTherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is $0.06, while revenue estimate is $17.87M.
Earnings released on 14 Aug 2025
EPS came in at $0.00 falling short of the estimated $0.03 by -93.27%, while revenue for the quarter reached $15.66M , beating expectations by +16.11%.
Earnings released on 9 May 2025
EPS came in at -$0.05 falling short of the estimated $0.08 by -162.50%, while revenue for the quarter reached $10.11M , missing expectations by -56.22%.
Earnings released on 17 Mar 2025
EPS came in at $0.09 surpassing the estimated $0.07 by +28.57%, while revenue for the quarter reached $18.22M , missing expectations by -15.66%.
Earnings released on 14 Nov 2024
EPS came in at $0.03 falling short of the estimated $0.06 by -50.00%, while revenue for the quarter reached $17.96M , missing expectations by -1.36%.
Earnings released on 14 Aug 2024
EPS came in at -$0.03 falling short of the estimated -$0.01 by -250.06%, while revenue for the quarter reached $13.47M , beating expectations by +259.50%.
Earnings released on 10 May 2024
EPS came in at -$0.06 falling short of the estimated -$0.02 by -200.00%, while revenue for the quarter reached $3.75M , missing expectations by -59.26%.
Earnings released on 14 Mar 2024
EPS came in at -$0.07 falling short of the estimated -$0.03 by -133.33%, while revenue for the quarter reached $10.49M , beating expectations by +80.79%.
Earnings released on 6 Nov 2023
EPS came in at -$0.04 surpassing the estimated -$0.07 by +42.86%, while revenue for the quarter reached $10.35M , beating expectations by +27.40%.
Earnings released on 7 Aug 2023
EPS came in at $0.21 surpassing the estimated $0.03 by +624.89%, while revenue for the quarter reached $35.08M , beating expectations by +92.19%.
Earnings released on 4 May 2023
EPS came in at -$0.05 , while revenue for the quarter reached $9.59M .
Earnings released on 27 Feb 2023
EPS came in at -$0.07 surpassing the estimated -$0.15 by +53.33%, while revenue for the quarter reached $8.62M , beating expectations by +40.80%.
Earnings released on 14 Nov 2022
EPS came in at -$0.07 surpassing the estimated -$0.15 by +53.33%, while revenue for the quarter reached $14.18M , beating expectations by +149.04%.
Earnings released on 15 Aug 2022
EPS came in at -$0.11 surpassing the estimated -$0.18 by +38.89%, while revenue for the quarter reached $8.75M , beating expectations by +227.21%.
Earnings released on 16 May 2022
EPS came in at -$0.05 falling short of the estimated -$0.04 by -25.00%, while revenue for the quarter reached $16.09M , beating expectations by +3.77%.
Earnings released on 31 Mar 2022
EPS came in at -$0.14 falling short of the estimated -$0.11 by -27.27%, while revenue for the quarter reached $8.55M , beating expectations by +9.74%.
Earnings released on 15 Nov 2021
EPS came in at -$0.09 surpassing the estimated -$0.12 by +25.00%, while revenue for the quarter reached $12.05M , beating expectations by +54.74%.
Earnings released on 16 Aug 2021
EPS came in at -$0.25 falling short of the estimated -$0.08 by -212.50%, while revenue for the quarter reached $6.43M , missing expectations by -6.86%.
Earnings released on 14 May 2021
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%, while revenue for the quarter reached $11.32M , beating expectations by +3.38%.
Earnings released on 30 Mar 2021
EPS came in at $0.03 surpassing the estimated -$0.09 by +133.33%, while revenue for the quarter reached $19.50M .
Earnings released on 29 Oct 2020
EPS came in at -$0.14 falling short of the estimated -$0.08 by -75.00%, while revenue for the quarter reached $10.79M , beating expectations by +7.74%.
PLX Stock Performance
Access detailed PLX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.